Science & Technology

Channels: Science & Technology | Financial Markets | Artificial Intelligence | Blockchain


Glympse Bio Presents Preclinical Data Supporting Its Technology’s Potential to Improve NASH Patient Management

[2019.11.08, Fri 15:03] CAMBRIDGE, Mass.-(Business Wire)-Glympse Bio, Inc., a life science company developing a non-invasive technology to directly query disease activity inside the body, today announced the presentation of preclinical data in support of the Glympse Liver Test in enabling early identification of disease stage, monitoring of fibrosis progression and early detection of drug-induced liver protection in NASH with high diagnostic accuracy. "These preclinical results support the advancement of our proprietary synthetic biomarkers as we prepare to move into NASH clinical trials," said Caroline J Loew, PhD, President and CEO, Glympse Bio. "NASH patient management is limited today by reliance on invasive procedures, and with the growth of the NASH population, a non-invasive alternative could provide significant benefit. We look forward to continuing to develop our innovative technology to transform patient health with earlier measures of disease and treatment." The Glympse Liver Test, is a multiplexed, injectable mixture of sensors that specifically detect the activity of proteases linked to NASH, used to monitor disease severity and treatment response. GLT effectively identified disease with a fibrosis score of 2 or above and detected disease progression as early as 4 weeks. The data supports that GLT enables early monitoring and staging of fibrosis progression and drug-induced hepatoprotection in NASH with high diagnostic accuracy, without the need for a biopsy. ABOUT GLYMPSE BIO, INC. Glympse Bio is pioneering the development of disruptive, non-invasive technology to directly query disease activity inside the body.
Read on Digital Journal >   Google the news >>

<< Back


(c) 2019 Geo Glance